• Rhythm Biosciences receives $1M non-dilutive funding from Endpoints Capital
• Funding secured against the company's Research and Development Tax Incentive (RDTI)
• Funding to support ongoing operations, including commercial launch of new ColoSTAT® assay and geneType™ product line

Rhythm Biosciences Ltd (ASX:RHY), an Australian innovative, medical diagnostics company, has received a tranche of $1M in non-dilutive funding from Endpoints Capital ('EndPoints') under a funding facility secured against the Company's Research and Development Tax Incentive ('RDTI'). The total funding approved is $1.14M, with the $1M drawdown being repayable via the FY25 RDTI Rebate, anticipated later in 2025. The funding will be used to support ongoing operations, including the planned commercial launch of the new, multiplex assay version of ColoSTAT®, commercial sales distribution activities for geneType™, further R&D studies into other cancer diagnostics, developing and securing partnerships, and day-to-day working capital requirements. The Australian Government RDTI program provides eligible companies with a rebate against research and development related expenditure by way of refundable tax offset. The funding from Endpoints is seen as a strong vote of confidence in Rhythm Biosciences' RDTI program and will help accelerate the company's momentum as it hits key milestones for ColoSTAT® and expands the geneType™ product line's pipeline and customer base.

The funding from Endpoints will help accelerate Rhythm Biosciences' momentum as it hits key milestones for ColoSTAT® and expands the geneType™ product line's pipeline and customer base.